

SUPPLEMENTARY TABLE 1: COMPARING CLINICAL FEATURES AND OUTCOMES BETWEEN LOCAL CASE SERIES AND REPORTED CASES IN THE LITERATURE

	Case Series <i>n</i> =8	Literature <i>n</i> =80
Age (yr)	60 ± 11	49 ± 15
Sex , <i>n</i> (%)		
Male	6 (75.0)	36 (45.0)
Hormonal excess, <i>n</i> (%)	3 (37.5)	34 (42.5)
Site, <i>n</i> (%)		<i>n</i> =78
Left	4 (50.0)	52 (66.7)
Size (mm)	120.7 ± 52.0	<i>n</i> =74 117.7 ± 53.43
Weight (g)	328 (63.5-1893)	<i>n</i> =64 410 (8-5720)
Mitotane, <i>n</i> , (%)	4 (50.0)	21 (42.8)
Radiotherapy alone <i>n</i> , (%)	0	<i>n</i> = 48 5 (10.4)
Chemotherapy alone <i>n</i> , (%)	1 (12.5)	1 (2.0)
Radiotherapy & Chemotherapy <i>n</i> , (%)	1 (12.5)	1 (2.0)
Recurrence/Metastases, <i>n</i> , (%)		<i>n</i> = 58
Yes	3 (37.5)	17 (29.3)
Outcome, <i>n</i> (%)		<i>n</i> = 74
DOD	1 (12.5)	12 (16.2)
AED	2 (25.0)	10 (13.5)
ANED	5 (62.5)	51 (68.9)
DNOD	0 (0.0)	1 (1.3)

DOD= Dead of disease, AED= Alive with evidence of disease, ANED= Alive with no evidence of disease, DNOD=Died not of disease